SYNLAB UK & Ireland:

Modern Slavery & Human Trafficking Statement – 2026

Published: 18th February 2026 - All information correct at time of publication.

Introduction

This Modern Slavery and Human Trafficking Statement sets out the actions taken by SYNLAB UK & Ireland to identify, prevent, and address risks of modern slavery within our operations and supply chains during the 2025 financial year.

Our Organisational Structure, Bussiness Model & Supply Chain

SYNLAB Group offer services in more than 20 countries across four continents (Europe, Latin America, Africa and Middle East/Asia), having more than 24,000 employees including 3,000 employees across the UK & Ireland.

SYNLAB UK & Ireland’s operating business activities provide analytical, diagnostic and pathological services in the fields of human medicine and toxicology.

SYNLAB UK & Ireland is an umbrella term for SYNLAB Bondco Plc, Labco UK Group Limited, the head office company for SYNLAB International GmbH in the UK, subsidiary companies of Labco UK Group Limited and partnerships in which SYNLAB has a controlling share:

  • Integrated Pathology Partnerships Limited, iPP Analytics Limited, iPP Facilities Limited.
  • Christie Pathology Partnerships LLP and CPP Facilities LLP.
  • Synnovis Group LLP, Synnovis Services LLP and Synnovis Analytics LLP.

In providing our services, we rely on the supply of technical equipment provided by suppliers of analytical machinery and technology for laboratory analyses/diagnostic testing, as well as reagents, chemicals and laboratory consumables utilised in such testing.

Goods and services are provided by professional services companies, subcontractors including couriers and sub-processors of test samples. In addition, we rely on external professional services providers in relation to our head office support, including financing related activities as well as its corporate and financial housekeeping.

Our Policies

SYNLAB UK & Ireland is committed to ensuring that the supply chains of its subsidiaries and their business activities trade ethically, source responsibly and work to prevent modern slavery and human trafficking throughout our organisation and supply chain.

We have a Code of Conduct, issued to all new employees, setting out our commitment to act ethically and with integrity in all our business relationships. There is also a dedicated policy on anti-slavery and human trafficking. All our employees must comply with all relevant laws and regulations (including those on modern slavery and human trafficking) and they must respect the personal dignity, rights, and diversity of everyone within and outside of SYNLAB.

We utilise SYNLAB Group’s Supplier Code of Conduct, introduced as part of its plans for Responsible Supply Chain management. Key principles include advocacy for anti-slavery training and ensuring purchasing practices do not put undue pressure on suppliers. In 2023 the Group also implemented an updated global ‘Speak Up’ reporting arrangements to encourage workers to “speak-up about their concerns knowing that there is protection from reprisals in place”. This was further supported in 2023 by the launch of SYNLAB Group’s Human Rights Strategy, policies and practices which flow down into SYNLAB UK & Ireland’s operations, which was reissued in December 2025.

Due Diligence & Risk Assessment

We acknowledge that slavery and human trafficking exist in many jurisdictions in which we operate, and/or from which we procure goods or services. Our overall objective is to establish and maintain relationships with our suppliers that will minimise the risk that slavery or human trafficking could occur within our supply chains.

Our due diligence approach is based on the inclusion of our relevant functional teams, such as legal, compliance, and procurement at the earliest stages of tendering and ensuring they have advanced levels of training in this and other ethical business areas. We are continuing to support efforts to tackle modern slavery by implementing various instruments, including the introduction of Modern Slavery Act (MSA) provisions in our supplier contracts and the circulation of supplier assessment questionnaires.

To mitigate against the risk of modern slavery and human trafficking in our supply chain, risk assessments and due diligence will continue to focus on our first-tier supplier relationships. Our risk-based approach to supply chain management has identified that international suppliers of laboratory consumables are our priority. All parts of our business use this group of suppliers and therefore this is a priority area to audit against our code of conduct.

We are continuously taking steps to improve our systems and procedures to detect potential modern slavery and human trafficking risks arising around particular products and geographical areas. Our efforts are overseen by SYNLAB Group, who has a dedicated Compliance Committee consisting of the Group Chief Executive Officer and Group Chief Financial Officer, chaired by the Group Chief Compliance Officer. The Compliance Committee is supported by Regional Compliance Officers, which includes the Head of Legal and Compliance for SYNLAB UK & Ireland.

Effective Actions Taken

We use the following key performance indicators (“KPIs”) to measure how effective we have been to ensure that slavery and human trafficking is not taking place in any part of our business or supply chain:

Supplier engagement: All new supplier contracts include an anti-slavery and human trafficking clause; our KPI in this area is to achieve 100% adherence. In addition, we have amended procurement contracts of our top global first tier supplier to confirm MSA compliance within our supply chain.

Training: To ensure a high level of understanding of the risks of modern slavery and human trafficking in our supply chains and our business, all current employees in the UK have to complete a training module annually on modern slavery and human trafficking. New employees must complete this training within the first two weeks of their employment with SYNLAB UK & Ireland. Our target is that 95% of employees, at any one time, will have completed this training module over the previous 12 months.

Supplier Questionnaire: We have issued our supplier questionnaire to our suppliers as a mandatory feature of our onboarding process. This now forms part of our supplier selection and on-boarding process that will be subject to audit from 2025 onwards to ensure this control is operating effectively.

Complaints/Concerns: We will take any concerns raised about modern slavery either within our workplaces, our supply chain or the communities in which we operate seriously and provide access to a confidential, independent, free method of reporting these concerns. Our target is to have zero concerns.

Looking Ahead

We understand that combating modern slavery and human trafficking is an ongoing imperative. In 2026, we will continue to invest in doing so.

Thomas Evans

Director

Labco UK Group Limited

For our 2025 Modern Slavery and Human Trafficking Statement please click here

Latest SYNLAB UK & Ireland News
SYNLAB UK&I appoints new Synnovis CEO

SYNLAB UK & Ireland is delighted to announce the appointment of Tom Evans as Chief Executive Officer of Synnovis, its NHS partnership in South East…

Read More (about 'SYNLAB UK&I appoints new Synnovis CEO')
SYNLAB UK & Ireland partners with iFAST Diagnostics

We are proud to announce the expansion of our partnership with iFAST Diagnostics as its first commercial laboratory partner in the UK. Following validation earlier…

Read More (about 'SYNLAB UK & Ireland partners with iFAST Diagnostics')
SYNLAB UK & Ireland announces new Chief Medical Officer

SYNLAB UK & Ireland is delighted to announce the appointment of Dr John Burke as Chief Medical Officer. This appointment is pivotal to the advancement…

Read More (about 'SYNLAB UK & Ireland announces new Chief Medical Officer')
iFAST Diagnostics

We are proud to be partnering with iFAST Diagnostics to evaluate their new antimicrobial susceptibility testing (AST) system. The low-cost, high-throughput, bench top device can…

Read More (about 'iFAST Diagnostics')
Synnovis Logo
Synnovis completes forensic review following 2024 cyberattack — notifications under way

Synnovis, a pathology partnership between Guy’s and St Thomas’ NHS Foundation Trust, King’s College Hospitals NHS Trust and SYNLAB, has completed the forensic investigation of…

Read More (about 'Synnovis completes forensic review following 2024 cyberattack — notifications under way')
A single pathology service for mid and south Essex is confirmed from October 2026

Mid and South Essex NHS Foundation Trust has signed a 15-year contract with SYNLAB, one of UK’s leading laboratory diagnostics providers, for the delivery of…

Read More (about 'A single pathology service for mid and south Essex is confirmed from October 2026')
The Christie NHS Foundation Trust & SYNLAB announce new 15+ year contract

The Christie NHS Foundation Trust has signed a 15+ year contract with SYNLAB, the leading provider of medical diagnostic services and specialty testing in Europe,…

Read More (about 'The Christie NHS Foundation Trust & SYNLAB announce new 15+ year contract')
SYNLAB Chosen as Preferred Pathology Services Supplier for Mid and South Essex

Patients across mid and south Essex are set to benefit from a single provider of pathology services, following an intensive and competitive procurement process. SYNLAB,…

Read More (about 'SYNLAB Chosen as Preferred Pathology Services Supplier for Mid and South Essex')
SYNLAB Values Wheel
SYNLAB sets its Sights on Becoming the UK’s Leading Laboratory Diagnostics Organisation

Science for Life, Health and Wellbeing SYNLAB, the medical diagnostics provider, has set out its ambition to become the UK’s leading  laboratory diagnostics organisation by…

Read More (about 'SYNLAB sets its Sights on Becoming the UK’s Leading Laboratory Diagnostics Organisation')
Landmark Day for Pathology Partnership with Launch of Synnovis Brand

A pathology partnership performing 32 million tests a year has been relaunched as ‘Synnovis’ – officially heralding the start of a new era for clinicians…

Read More (about 'Landmark Day for Pathology Partnership with Launch of Synnovis Brand')
Pathology laboratory becomes the first in the UK to support remote plate reading  

A pathology laboratory is leading the way in speeding up access to patient care and treatment after becoming the first in the UK to enable…

Read More (about 'Pathology laboratory becomes the first in the UK to support remote plate reading  ')
SYNLAB ESG Roadmap and Framework

Introduction SYNLAB UK&I is thrilled to publish its UK&I ESG Framework and Roadmap, which outlines out how we will achieve our ESG Goals. In it…

Read More (about 'SYNLAB ESG Roadmap and Framework')